Pfizer (PFE) risk factors, FY2025 10-K

Pfizer's FY2025 10-K, filed Feb 26, 2026, lists 18 risk factors in 4 groups. Against the prior year's 16: 3 new, 1 dropped, 11 substantially reworded.

Open PFE in Gloom →
Pfizer's chart, financials and news, free in your browser.Open PFE in Gloom →
Risk factors listed
184 groups
New this year
3vs 16 last year
Dropped
1since the prior 10-K
Substantially reworded
11of those kept
Section length
13k wordsItem 1A

What the changes say

  • OBBBA healthcare funding cuts could increase pricing controls and reduce demand, with CBO estimating 10 million more uninsured people.
  • Pfizer highlights aggressive generic and biosimilar challenges, including at-risk launches, China price cuts and volume losses.
  • Climate risk now includes physical threats such as drought, flooding, wildfires and storms disrupting production and medicine supply chains.
  • Pricing risks broaden to international reference pricing, mandatory rebates, CMMI pilots, and reduced ACA subsidies or Medicaid funding.

What changed since the prior 10-K

New

  • NewRISKS RELATED TO OUR BUSINESS, INDUSTRY AND OPERATIONS

    section. In China, we expect to continue to face intense competition by certain generic manufacturers, which has resulted, and may result in the future, in price cuts and volume loss of some of our products

    Chinese generic competition and at-risk generic or biosimilar launches could cut prices, volumes and patent-protected product sales.

  • NewRISKS RELATED TO INTELLECTUAL PROPERTY, TECHNOLOGY AND SECURITY

    Further, legal or regulatory action by various stakeholders or governments could potentially result in us not seeking intellectual property protection for or agreeing not to enforce or being restricted from enforcing intellectual property related to our products

    Government or legal actions could restrict Pfizer’s ability to obtain or enforce product patents across countries with weaker protections or compulsory licensing.

  • NewGENERAL RISKS

    RESPONSIBLE BUSINESS PRACTICES

    Climate transition and physical hazards could raise energy and compliance costs, disrupt pharmaceutical production and interrupt medicine supply chains.

Dropped

  • DroppedGENERAL RISKS

    RESPONSIBLE BUSINESS GROWTH

Reworded

  • 75% rewrittenRISKS RELATED TO INTELLECTUAL PROPERTY, TECHNOLOGY AND SECURITY

    INTELLECTUAL PROPERTY PROTECTION

    No substantive change; Pfizer continues to rely on patents and other intellectual property protections against generic, biosimilar and similar products.

  • 58% rewrittenGENERAL RISKS

    CHANGES IN LAWS AND ACCOUNTING STANDARDS

    Adds the OBBBA, government cost-cutting and staffing effects, data-transfer restrictions, country-related transaction limits and further regulatory changes.

  • 51% rewrittenRISKS RELATED TO GOVERNMENT REGULATION AND LEGAL PROCEEDINGS

    PRICING AND REIMBURSEMENT

    Adds international reference pricing including MFN, higher required rebates, mandatory CMMI pilots, and potential ACA subsidy and Medicaid funding cuts.

  • 46% rewrittenRISKS RELATED TO INTELLECTUAL PROPERTY, TECHNOLOGY AND SECURITY

    INFORMATION TECHNOLOGY AND CYBERSECURITY

    No substantive change; Pfizer continues to face disruption and breach risks involving systems, confidential information, digital tools and cloud services.

    Was: INFORMATION TECHNOLOGY AND SECURITY

  • 44% rewrittenGENERAL RISKS

    Changes in the fair value of certain equity investments that are recognized in net income may result in increased volatility of our income. See Note 4 and the Analysis of Financial Condition, Liquidity, Capital Resources and Market Risk section within MD&A

    Recasts the risk around pension and postretirement plans and clarifies that discount rates measure plan obligations.

  • 41% rewrittenRISKS RELATED TO GOVERNMENT REGULATION AND LEGAL PROCEEDINGS

    U.S. HEALTHCARE REGULATION

    Adds OBBBA cuts to Medicaid, Health Insurance Marketplaces and the Medicare Physician Fee Schedule, potentially increasing controls and reducing demand.

  • 28% rewrittenRISKS RELATED TO OUR BUSINESS, INDUSTRY AND OPERATIONS

    PRODUCT MANUFACTURING, SALES AND MARKETING RISKS

    No substantive change; the same manufacturing, supply-chain, distribution, sales and marketing disruption risks remain.

  • 27% rewrittenRISKS RELATED TO GOVERNMENT REGULATION AND LEGAL PROCEEDINGS

    DEVELOPMENT, REGULATORY APPROVAL AND MARKETING OF PRODUCTS

    No substantive change; Pfizer continues to cite costly, lengthy development, enrollment difficulties and clinical or preclinical failures.

  • 24% rewrittenRISKS RELATED TO OUR BUSINESS, INDUSTRY AND OPERATIONS

    We may become subject to competition from biosimilars referencing our biologic products if competitors are able to obtain marketing approval for such biosimilars

  • 24% rewrittenRISKS RELATED TO GOVERNMENT REGULATION AND LEGAL PROCEEDINGS

    POST-AUTHORIZATION/APPROVAL DATA

  • 20% rewrittenGENERAL RISKS

    BUSINESS DEVELOPMENT ACTIVITIES AND STRATEGIC GOALS

All 18 risk factors

Headings as the filing states them, in filing order.

RISKS RELATED TO OUR BUSINESS, INDUSTRY AND OPERATIONS

  1. 01section. In China, we expect to continue to face intense competition by certain generic manufacturers, which has resulted, and may result in the future, in price cuts and volume loss of some of our productsNew
  2. 02We may become subject to competition from biosimilars referencing our biologic products if competitors are able to obtain marketing approval for such biosimilars24% rewritten
  3. 03PRODUCT MANUFACTURING, SALES AND MARKETING RISKS28% rewritten
  4. 04COLLABORATIONS AND OTHER RELATIONSHIPS WITH THIRD PARTIES

RISKS RELATED TO GOVERNMENT REGULATION AND LEGAL PROCEEDINGS

  1. 05PRICING AND REIMBURSEMENT51% rewritten
  2. 06U.S. HEALTHCARE REGULATION41% rewritten
  3. 07DEVELOPMENT, REGULATORY APPROVAL AND MARKETING OF PRODUCTS27% rewritten
  4. 08POST-AUTHORIZATION/APPROVAL DATA24% rewritten

RISKS RELATED TO INTELLECTUAL PROPERTY, TECHNOLOGY AND SECURITY

  1. 09INTELLECTUAL PROPERTY PROTECTION75% rewritten
  2. 10Further, legal or regulatory action by various stakeholders or governments could potentially result in us not seeking intellectual property protection for or agreeing not to enforce or being restricted from enforcing intellectual property related to our productsNew
  3. 11THIRD-PARTY INTELLECTUAL PROPERTY CLAIMS
  4. 12INFORMATION TECHNOLOGY AND CYBERSECURITY46% rewritten

GENERAL RISKS

  1. 13BUSINESS DEVELOPMENT ACTIVITIES AND STRATEGIC GOALS20% rewritten
  2. 14RESPONSIBLE BUSINESS PRACTICESNew
  3. 15Changes in the fair value of certain equity investments that are recognized in net income may result in increased volatility of our income. See Note 4 and the Analysis of Financial Condition, Liquidity, Capital Resources and Market Risk section within MD&A44% rewritten
  4. 16COST AND EXPENSE CONTROL AND UNUSUAL EVENTS
  5. 17INTANGIBLE ASSETS, GOODWILL AND EQUITY-METHOD INVESTMENTS
  6. 18CHANGES IN LAWS AND ACCOUNTING STANDARDS58% rewritten

Other Pfizer 10-Ks

  • FY2024 10-K risk factors
    16 risks

    Pfizer faces heavy exposure to pricing pressure from biosimilars and government price controls under U.S. and international regulations. The company relies heavily on third-party collaborators and complex supply chains for manufacturing and distribution. Pipeline development carries high clinical trial risks alongside substantial intangible asset and intellectual property exposures.

    Filed Feb 27, 2025

About this page

The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.